AstraZeneca PLC

AZN

Cena:

$ 187.03

-2.72 (-1.43%)

Valuace

Růst

Zdraví

Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři

Souhrn

Finanční data

Pro investory

Předpovědi

Zprávy

Dividendy

Zisky

Návštěvnost webu

Akcionáři

Zprávy

Zahraniční články

Tiskové zprávy

Dokumenty ke stáhnutí

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

7:00 22-05-2026

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause ...

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

6:45 22-05-2026

A European ‌Medicines Agency committee said on ⁠Friday it has adopted a positi...

AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings

13:31 18-05-2026

AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer tr...

AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy

13:01 18-05-2026

AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled...

Cancer Stocks That Are Advancing the Future of Oncology Care

13:01 18-05-2026

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-...

AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug

8:02 18-05-2026

AstraZeneca (AZN) has won US FDA approval for Baxfendy, giving the drugmaker a potentially important...

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

7:00 18-05-2026

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the U...

AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu

2:55 18-05-2026

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class...

AstraZeneca Gets U.S. Approval for Hypertension Drug

2:13 18-05-2026

The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at...

AstraZeneca's blood pressure drug wins U.S. approval

2:01 18-05-2026

Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approve...

Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

13:41 15-05-2026

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, div...

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

2:59 14-05-2026

AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy...

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

8:20 01-05-2026

The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed re...

AstraZeneca stock falls after FDA panel votes against new cancer drug

5:51 01-05-2026

An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral dru...

AstraZeneca falls as FDA advisers reject breast cancer drug use

5:01 01-05-2026

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory ...

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

3:56 01-05-2026

The British pharmaceutical group said it would continue to work with U.S. regulators on a review of ...

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

3:09 01-05-2026

Shares of AstraZeneca fell ‌1.7% on Friday after an advisory ⁠panel for the U.S. ...

AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom

14:24 30-04-2026

Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker r...

FDA panel votes against backing AstraZeneca's breast cancer drug

13:48 30-04-2026

A panel ⁠of outside experts to the U.S. Food and Drug Administration voted against ‌...

Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts

8:47 30-04-2026

Bank lifts 2026 core earnings per share estimate 2% to $10.30 after first-quarter beat, sees positiv...

ASTRAZENECA AWARDS $3.4 MILLION FOR PROGRAMS TO IMPROVE ACCESS TO HEALTHCARE FOR PATIENTS ACROSS THE US

11-02-2026

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA HAS PROUDLY AWARDED $3.4 MILLION TO NONPROFIT ORGANIZ...

Více zde

ASTRAZENECA RESULTS: FY AND Q4 2025

10-02-2026

CAMBRIDGE, ENGLAND--(BUSINESS WIRE)--ASTRAZENECA: REVENUE AND EPS SUMMARY FY 2025 % CHANGE Q4 202...

Více zde

ASTRAZENECA BEGINS TRADING ON THE NEW YORK STOCK EXCHANGE

02-02-2026

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA TODAY BEGINS TRADING ITS ORDINARY SHARES ON THE NEW Y...

Více zde

UNIVERSITY OF VIRGINIA SIGNS MASTER RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA TO ACCELERATE PRE-CLINICAL INNOVATION

28-01-2026

AGREEMENT BUILDS ON LONG-ESTABLISHED PARTNERSHIP AND DEMONSTRATES THE STRENGTH AND IMPORTANCE OF IND...

Více zde

BIOTECH VETERAN AND VIROLOGIST JOINS CANCERVAX AS SENIOR SCIENTIFIC ADVISOR

27-01-2026

DR. GEORGE KEMBLE, FORMER ASTRAZENECA EXECUTIVE, TO ADVISE THE COMPANY ON IMMUNOLOGICAL AND VIRAL ST...

Více zde

MODELLA AI ANNOUNCES ACQUISITION BY ASTRAZENECA TO ADVANCE AI-DRIVEN ONCOLOGY R&D AT GLOBAL SCALE

13-01-2026

BOSTON--(BUSINESS WIRE)-- #ASTRAZENECA--MODELLA AI ANNOUNCES ACQUISITION BY ASTRAZENECA TO ADVANCE A...

Více zde

RICK R. SUAREZ APPOINTED US PRESIDENT AND HEAD OF US BIOPHARMACEUTICALS BUSINESS UNIT

08-01-2026

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA HAS NAMED RICK R. SUAREZ SENIOR VICE PRESIDENT, US PR...

Více zde

BOSTONGENE AND ASTRAZENECA ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE FOUNDATION MODEL-DRIVEN ONCOLOGY DEVELOPMENT

06-01-2026

WALTHAM, MASS.--(BUSINESS WIRE)--BOSTONGENE, THE DEVELOPER OF THE LEADING AI FOUNDATION MODEL FOR TU...

Více zde

ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) PLUS PERTUZUMAB APPROVED IN THE US AS FIRST NEW TREATMENT IN A DECADE FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

15-12-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA AND DAIICHI SANKYO'S ENHERTU® (FAM-TRASTUZUMAB DERUX...

Více zde

BIOINVENT PRESENTS IMPRESSIVE RESPONSE DATA FROM ONGOING PHASE 2A TRIAL OF TRIPLE COMBINATION BI-1206, RITUXIMAB, AND CALQUENCE IN R/R NHL AT ASH 2025

08-12-2025

EARLY DATA INDICATE THAT BI-1206 HAS THE POTENTIAL TO RESET ONE OF THE MAIN RESISTANCE MECHANISMS TO...

Více zde

SALESFORCE'S AGENTFORCE LIFE SCIENCES SELECTED BY ASTRAZENECA AS ITS UNIFIED GLOBAL PLATFORM TO HELP TRANSFORM CUSTOMER ENGAGEMENT

04-12-2025

SAN FRANCISCO--(BUSINESS WIRE)--SALESFORCE (NYSE: CRM), THE WORLD'S #1 CRM, TODAY ANNOUNCED THAT AST...

Více zde

ASTRAZENECA ADVANCES HEMATOLOGY AND CELL THERAPY AMBITION WITH LARGEST-EVER PRESENCE AT ASH

04-12-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA ADVANCES ITS AMBITION TO REDEFINE HEMATOLOGY CARE WIT...

Více zde

BAXDROSTAT NEW DRUG APPLICATION ACCEPTED UNDER FDA PRIORITY REVIEW IN THE US FOR PATIENTS WITH HARD-TO-CONTROL HYPERTENSION

02-12-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA'S NEW DRUG APPLICATION (NDA) FOR BAXDROSTAT HAS BEEN ...

Více zde

HARBOUR BIOMED ADVANCES GLOBAL STRATEGIC COLLABORATION WITH ASTRAZENECA TO DISCOVER AND DEVELOP NEXT-GENERATION BIOTHERAPEUTICS IN ONCOLOGY

23-11-2025

CAMBRIDGE, MASS., ROTTERDAM, NETHERLANDS AND SHANGHAI , NOV. 23, 2025 /PRNEWSWIRE/ -- HARBOUR BIOME...

Více zde

ASTRAZENECA PLANS $2 BILLION MANUFACTURING INVESTMENT IN MARYLAND, SUPPORTING 2,600 JOBS AND CATALYZING ECONOMIC GROWTH

21-11-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA TODAY ANNOUNCES PLANS TO INVEST $2 BILLION TO EXPAND ...

Více zde

BAXDROSTAT DEMONSTRATED A STATISTICALLY SIGNIFICANT AND HIGHLY CLINICALLY MEANINGFUL PLACEBO-ADJUSTED REDUCTION OF 14.0 MMHG IN 24-HOUR AMBULATORY SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH RESISTANT HYPERTENSION IN THE BAX24 PHASE III TRIAL

09-11-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--POSITIVE FULL RESULTS FROM THE BAX24 PHASE III TRIAL SHOWED BAXDR...

Více zde

STATISTICALLY SIGNIFICANT NATRON PHASE III TRIAL RESULTS FOR HYPEREOSINOPHILIC SYNDROME SHOW FASENRA DELAYED TIME TO FIRST FLARE OR WORSENING OF DISEASE

07-11-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--POSITIVE FULL RESULTS FROM THE NATRON PHASE III TRIAL SHOWED ASTR...

Více zde

ASTRAZENECA'S 9M AND Q3 2025 FINANCIAL RESULTS

06-11-2025

CAMBRIDGE, ENGLAND--(BUSINESS WIRE)--Q3 2025 RESULTS RELEASE....

Více zde

BIOINVENT TO PRESENT EARLY PHASE 2A DATA FROM ONGOING TRIAL WITH TRIPLE COMBINATION OF BI-1206, RITUXIMAB, AND CALQUENCE IN R/R NHL, AT ASH 2025

03-11-2025

LUND, SE / ACCESS NEWSWIRE / NOVEMBER 3, 2025 / BIOINVENT INTERNATIONAL AB ("BIOINVENT")(STO:BINV)(N...

Více zde

TEZSPIRE APPROVED IN THE US FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

17-10-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA AND AMGEN'S TEZSPIRE® (TEZEPELUMAB -EKKO) HAS BEEN A...

Více zde

ASTRAZENECA UNVEILS EXPANDED MANUFACTURING FACILITY IN TEXAS

15-10-2025

COPPELL, TEXAS--(BUSINESS WIRE)--ASTRAZENECA TODAY ANNOUNCES THE UNVEILING OF ITS NEWLY-EXPANDED, ST...

Více zde

ASTRAZENECA FURTHERS AMBITION TO REDEFINE CANCER CARE WITH FIRST DATA FROM FOUR MAJOR PIVOTAL TRIALS AT ESMO

13-10-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA ADVANCES ITS AMBITION TO REDEFINE CANCER CARE WITH NE...

Více zde

ASTRAZENECA PLANS TO INCREASE INVESTMENT AND SCOPE OF ITS VIRGINIA MANUFACTURING FACILITY TO $4.5 BILLION, CREATING 3,600 NEW JOBS

09-10-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA TODAY ANNOUNCES THAT IT WILL INVEST $4.5 BILLION IN I...

Více zde

TURBINE LAUNCHES COLLABORATION WITH ASTRAZENECA, LEVERAGING TURBINE'S VIRTUAL DISEASE MODELS TO RATIONALIZE ADC DISCOVERY

09-10-2025

LONDON, UK AND BUDAPEST, HUNGARY , OCT. 9, 2025 /PRNEWSWIRE/ -- TURBINE, A LEADING COMPANY SPECIALIZ...

Více zde

BAXDROSTAT MET THE PRIMARY ENDPOINT IN BAX24 PHASE III TRIAL IN PATIENTS WITH RESISTANT HYPERTENSION

07-10-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--POSITIVE HIGH-LEVEL RESULTS FROM THE BAX24 PHASE III TRIAL SHOWED...

Více zde

ALGEN BIOTECHNOLOGIES ANNOUNCES MULTI-TARGET PARTNERSHIP TO ADVANCE AI-POWERED DRUG DISCOVERY IN IMMUNOLOGY WITH ASTRAZENECA

06-10-2025

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--ALGEN BIOTECHNOLOGIES ANNOUNCES MULTI-TARGET PARTNERSHIP TO AD...

Více zde

THERMO FISHER SCIENTIFIC ANNOUNCES R&D PARTNERSHIP WITH ASTRAZENECA BIOVENTUREHUB

01-10-2025

WILMINGTON, N.C.--(BUSINESS WIRE)--THERMO FISHER SCIENTIFIC ANNOUNCES R&D PARTNERSHIP WITH ASTRAZENE...

Více zde

ASTRAZENECA LAUNCHES DIRECT-TO-CONSUMER PLATFORM TO EXPAND ACCESS TO MEDICATIONS FOR US PATIENTS, INCLUDING THOSE LIVING WITH CHRONIC CONDITIONS

26-09-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA TODAY ANNOUNCES THE LAUNCH OF ASTRAZENECA DIRECT, AN ...

Více zde

ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) PLUS PERTUZUMAB GRANTED PRIORITY REVIEW IN THE US AS 1ST-LINE TREATMENT FOR PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

24-09-2025

WILMINGTON, DEL.--(BUSINESS WIRE)--ASTRAZENECA AND DAIICHI SANKYO'S SUPPLEMENTAL BIOLOGICS LICENSE A...

Více zde

SOPHIA GENETICS EXPANDS COLLABORATION WITH ASTRAZENECA TO ENHANCE DETECTION OF BREAST AND PROSTATE CANCER

22-09-2025

BOSTON , SEPT. 22, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), AN AI TECHNOLOGY COMPANY TR...

Více zde

Dokumenty nejsou k dispozici